Study Reveals Evidence Of Existing Diabetes Therapies For Newly Diagnosed Patients

December 05, 2006

The Canadian Diabetes Association says Canadians who are newly diagnosed with type 2 diabetes could now benefit from the findings of a new study examining the effectiveness of three commonly prescribed medications.

A Diabetes Outcome Progression Trial, which was released today, showed rosiglitazone to be more effective than metformin or glyburide in slowing the progression to hyperglycemia in people newly diagnosed with type 2 diabetes.

Donna Lillie, Vice-President of Research and Professional Education with the Canadian Diabetes Association said, "There is a growing epidemic of type 2 diabetes in Canada; almost two million Canadians have been diagnosed with diabetes, of which 90 per cent have type 2. The ADOPT study is an important part of our continually growing body of clinical evidence of how best to treat patients with type 2 diabetes."